Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Crinetics Pharmaceuticals Inc is a biotechnology business based in the US. Crinetics Pharmaceuticals shares (CRNX) are listed on the NASDAQ and all prices are listed in US Dollars. Crinetics Pharmaceuticals employs 93 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $24.01 |
|---|---|
| 52-week range | $13.83 - $28.95 |
| 50-day moving average | $26.29 |
| 200-day moving average | $21.33 |
| Wall St. target price | $43.83 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.79 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $24.01 from 2022-01-14
| 1 week (2022-01-10) | -3.50% |
|---|---|
| 1 month (2021-12-16) | 0.33% |
| 3 months (2021-10-18) | 24.08% |
| 6 months (2021-07-16) | 21.75% |
| 1 year (2021-01-15) | 68.97% |
|---|---|
| 2 years (2020-01-17) | 0.92% |
| 3 years (2019-01-18) | 4.39% |
| 5 years (2017-01-14) | N/A |
| Gross profit TTM | $-56,927,000 |
|---|---|
| Return on assets TTM | -30.09% |
| Return on equity TTM | -51.73% |
| Profit margin | 0% |
| Book value | $5.01 |
| Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Crinetics Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Crinetics Pharmaceuticals's shares have ranged in value from as little as $13.83 up to $28.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crinetics Pharmaceuticals's is 1.3436. This would suggest that Crinetics Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California. .
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.